Research Divisions

Research in Psychiatry

Group LeaderLocation and ContactMembersLines of ResearchNotable PublicationsProjectsPhD ThesesClinical TrialsPatents and TrademarksNews

Professor Julio Bobes García

Professor of Psychiatry at the Universidad de Oviedo, Julio Bobes García is currently Head of the Psychiatry Division in the university’s Department of Medicine, and Head of the Psychiatry Department for the Health District of Oviedo (Spain). He is also principal investigator of CIBERSAM (Network Centre for Biomedical Research: Mental Health) in Oviedo, Director of ISPA’s Neuroscience research division and President of the Real Academia de Medicina del Principado de Asturias (Royal Academy of Medicine of Asturias).

His work includes teaching, research and clinical practice.

He has published over 300 articles and is author and coordinator of several books, as well as a collaborator on a large number of book chapters.

His research interests include diverse aspects of the evaluation, management, treatment and impact of a range of psychiatric disorders: addictions, and psychotic, affective, anxiety and psychophysiological disorders. He also participates actively in the study and prevention of suicidal behaviours.

He is a member of a range of scientific societies within and outside Spain, in several of which he has held leadership positions, including board member of the European Psychiatric Association (EPA) and president of: the Sociedad Española de Psiquiatría Biológica (Spanish Society of Biological Psychiatry); the Consejo Español del Cerebro (Spanish Brain Council), which is part of the European Brain Council; Socidrogalcohol (Drug-Alcohol Society); the Sociedad Española para el Estudio de los Trastornos de Personalidad (Spanish Society for the Study of Personality Disorders) and, currently, the Sociedad Española de Psiquiatría (Spanish Psychiatry Society).

He participates in the editorial boards of high-impact publications and is editor-in-chief of the Psiquiatría y Salud Mental journal (IF 2017: 2.233).

Departamento de Medicina – Área de Psiquiatría

Universidad de Oviedo

C/ Julián Clavería s/n – 33006 Oviedo, Spain.

Telephone: +34 985103553

E-mail: bobes@uniovi.es

Name Position
María Paz García-Portilla González Universidad de Oviedo; Psychiatry Consultant
Pilar Alejandra Saiz Martínez Universidad de Oviedo; Psychiatry Consultant
Celso Iglesias García SESPA; Psychiatry Consultant
Luis Jiménez Treviño SESPA; Psychiatry Consultant
Isabel Menéndez Miranda SESPA; Psychiatry Consultant
Leticia González Blanco SESPA
Julia Rodríguez Revuelta SESPA
María Teresa Bascarán Fernández CIBER (Network Centre for Biomedical Research), Instituto de Salud Carlos III
Lorena de la Fuente Tomás Universidad de Oviedo, Severo Ochoa grant-holder; Psychologist
María Jose González García Portilla FINBA
Clara Martínez Cao Universidad de Oviedo, Severo Ochoa grant-holder
Manuel Bousoño García Psychiatry Consultant
Elisa Seijo Zazo Specialist Medical Professional (FEA) HGA-SESPA
María Suárez Álvarez SESPA
Leticia García Alvarez FINBA; Psychologist
María Teresa Bobes Bascarán SESPA; Consultant Clinical Psychologist
Sylvia Díaz Fernández
Juan José Fernández Miranda
Rocío Villa Díez Centro de Salud Mental (Mental Health Centre, CSM), Gijón
Francesco dal Santo Fourth-year Psychiatry Resident
Clara María Álvarez Vázquez Second-year Psychiatry Resident
Paula Zurrón Madera Mental Health Nurse, SESPA, CSM II

Mental and Behavioural Disorders
  1. Neurodevelopment (autistic spectrum disorder, attention deficit disorder and/or hyperactivity, schizophrenia, bipolar disorder, personality disorders)
  2. Neurodegeneration (dementia, alcoholism, severe depression, schizophrenia, bipolar disorder)
  3. Biomarkers:
    • Genetic
      • Epigenetic
      • Gene expression
    • CNV
    • Immuno-inflammatory (peripheral)
      Cytokines, oxidative stress, Apo-D
    • Microbiota: Zonulin, LPS, BPLS, citrulline
    • Brain imaging
    • Brain neurotransmitter systems

    Common disorders : anxiety disorders (panic disorder)

    Lines of research:

    • Functional markers:
      • Psychological and socio-occupational functions
      • Therapeutic innovation
        • Panic disorder: Methoxyflurane
        • Schizophrenia: Pimavanserin, Cariprazine, Minerva 101
Mental Health
  • Prevention
  • Psychometric assessment
  • Suicidal behaviours: prevention and management
  • Addictions: maintenance treatments
  1. AUTHORS: Carli V., Hoven C.W., Wasserman C., Chiesa F., Guffanti G., Sarchiapone M., Apter A., Balazs J., Brunner R., Corcoran P., Cosman D., Haring C., Iosue M., Kaess M., Kahn J.P., Keeley H., Postuvan V., Saiz P., Varnik A., Wasserman D.
    TITLE: A newly identified group of adolescents at “invisible” risk for psychopathology and suicidal behavior: Findings from the SEYLE study.
    World Psychiatry. 2014;13(1):78-86. IF 14.225
  2. AUTHORS: Garcia-Bueno B., Bioque M., Mac-Dowell K.S., Barcones M.F., Martinez-Cengotitabengoa M., Pina-Camacho L., Rodriguez-Jimenez R., Saiz P.A., Castro C., Lafuente A., Santabarbara J., Gonzalez-Pinto A., Parellada M., Rubio G., Garcia-Portilla M.P., Mico J.A., Bernardo M., Leza J.C.
    TITLE: Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: Toward an integrative inflammatory hypothesis of schizophrenia.
    Schizophrenia Bulletin. 2014;40(2):376-387. IF 8.450
  3. AUTHORS: Garcia-Portilla M.P., Garcia-Alvarez L., Mane A., Garcia-Rizo C., Sugranyes G., Berge D. et al.
    TITLE: The negative syndrome of schizophrenia: Three -underlying components are better than two.
    Schizophrenia Research. 2014;166(1-3):115-118. IF 3.923
  4. AUTHORS: Brunner R., Kaess M., Parzer P., Fischer G., Carli V., Hoven C.W., Wasserman C., Sarchiapone M., Resch F., Apter A., Balazs J., Barzilay S., Bobes J., Corcoran P., Cosmanm D., Haring C., Iosuec M., Kahn J.-P., Keeley H., Meszaros G., Nemes B., Podlogar T., Postuvan V., Saiz P.A., Sisask M., Tubiana A., Varnik A., Wasserman D.
    TITLE: Life-time prevalence and psychosocial correlates of adolescent direct self-injurious behavior: A comparative study of findings in 11 European countries.
    Journal of Child Psychology and Psychiatry and Allied Disciplines. 2014;55(4):337-348. IF 6.459
  5. AUTHORS: Van Os J., Rutten B.P., Myin-Germeys I., Delespaul P., Viechtbauer W., Van Zelst C., Bruggeman R., Reininghaus U., Morgan C., Murray R.M., Di Forti M., McGuire P., Valmaggia L.R., Kempton M.J., Gayer-Anderson C., Hubbard K., Beards S., Stilo S.A., Onyejiaka A., Bourque F., Modinos G., Tognin S., Calem M., O’Donovan M.C., Owen M.J., Holmans P., Williams N., Craddock N., Richards A., Humphreys I., Meyer-Lindenberg A., Leweke F.M., Tost H., Akdeniz C., Rohleder C., Bumb J.M., Schwarz E., Alptekin K., Ucok A., Saka M.C., Atbagoglu E.C., Guloksuz S., Gumus-Akay G., Cihan B., Karadag H., Soygur H., Cankurtaran E.S., Ulusoy S., Akdede B., Binbay T., Ayer A., Noyan H., Karadayi G., Akturan E., Ulas H., Arango C., Parellada M., Bernardo M., Sanjuan J., Bobes J., Arrojo M., Santos J.L., Cuadrado P., Solano J.J.R., Carracedo A., Bernardo E.G., Roldan L., Lopez G., Cabrera B., Cruz S., Mesa E.M.D., Pouso M., Jimenez E., Sanchez T., Rapado M., Gonzalez E., Martinez C., Sanchez E., Olmeda M.S., De Haan L., Velthorst E., Van Der Gaag M., Selten J.-P., Van Dam D., Van Der Ven E., Van Der Meer F., Messchaert E., Kraan T., Burger N., Leboyer M., Szoke A., Schurhoff F., Llorca P.-M., Jamain S., Tortelli A., Frijda F., Vilain J., Galliot A.-M., Baudin G., Ferchiou A., Richard J.-R., Bulzacka E., Charpeaud T., Tronche A.-M., De Hert M., Van Winkel R., Decoster J., Derom C., Thiery E., Stefanis N.C., Sachs G., Aschauer H., Lasser I., Winklbaur B., Schlogelhofer M., Riecher-Rossler A., Borgwardt S., Walter A., Harrisberger F., Smieskova R., Rapp C., Ittig S., Soguel-Dit-Piquard F., Studerus E., Klosterkotter J., Ruhrmann S., Paruch J., Julkowski D., Hilboll D., Sham P.C., Cherny S.S., Chen E.Y.H., Campbell D.D., Li M., Romeo-Casabona C.M., Cirion A.E., Mora A.U., Jones P., Kirkbride J., Cannon M., Rujescu D., Tarricone I., Berardi D., Bonora E., Seri M., Marcacci T., Chiri L., Chierzi F., Storbini V., Braca M., Minenna M.G., Donegani I., Fioritti A., La Barbera D., La Cascia C.E., Mule A., Sideli L., Sartorio R., Ferraro L., Tripoli G., Seminerio F., Marinaro A.M., McGorry P., Nelson B., Amminger G.P., Pantelis C., Menezes P.R., Del-Ben C.M., Tenan S.H.G., Shuhama R., Ruggeri M., Tosato S., Lasalvia A., Bonetto C., Ira E., Nordentoft M., Krebs M.-O., Barrantes-Vidal N., Cristobal P., Kwapil T.R., Brietzke E., Bressan R.A., Gadelha A., Maric N.P., Andric S., Mihaljevic M., Mirjanic T.
    TITLE: Identifying gene-environment interactions in schizophrenia: Contemporary challenges for integrated, large-scale investigations.
    Schizophrenia Bulletin. 2014;40(4):729-736. IF 8.450
  6. AUTHORS: Garcia-Portilla M.P., Bobes-Bascaran M.T., Bascaran M.T., Saiz P.A., Bobes J.
    TITLE: Long term outcomes of pharmacological treatments for opioid dependence: Does methadone still lead the pack?.
    British Journal of Clinical Pharmacology. 2014;77(2):272-284. IF 3.878
  7. AUTHORS: Stubbs B., Vancampfort D., Bobes J., De Hert M., Mitchell A.J.
    TITLE: How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview.
    Acta Psychiatrica Scandinavica. 2015;:-. IF 6.128
  8. AUTHORS: Gonzalez-Blanco L., Greenhalgh A.M.D., Garcia-Rizo C., Egea E.F., Miller B.J., Kirkpatrick B.
    TITLE: Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: A meta-analysis.
    Schizophrenia Research. 2015;:-. IF 4.4530
  9. AUTHORS: Wasserman D., Hoven C.W., Wasserman C., Wall M., Eisenberg R., Hadlaczky G., Kelleher I., Sarchiapone M., Apter A., Balazs J., Bobes J., Brunner R., Corcoran P., Cosman D., Guillemin F., Haring C., Iosue M., Kaess M., Kahn J.-P., Keeley H., Musa G.J., Nemes B., Postuvan V., Saiz P., Reiter-Theil S., Varnik A., Varnik P., Carli V.
    TITLE: School-based suicide prevention programmes: The SEYLE cluster-randomised, controlled trial.
    The Lancet. 2015;385(9977):1536-1544. IF 44.002
  10. AUTHORS: Menendez-Miranda I., Garcia-Portilla M.P., Garcia-Alvarez L., Arrojo M., Sanchez P., Sarramea F. et al.
    TITLE: Predictive factors of functional capacity and real-world functioning in patients with schizophrenia.
    European Psychiatry. 2015;30(5):622-627. IF 3.912
  11. AUTHORS: Garcia-Portilla M.P., Garcia-Alvarez L., Saiz P.A., Al-Halabi S., Bobes-Bascaran M.T., Bascaran M.T. et al.
    TITLE: Psychometric evaluation of the negative syndrome of schizophrenia.
    European Archives of Psychiatry and Clinical Neuroscience. 2015;265(7):559-566. IF 4.113
  12. AUTHORS: Zalsman G, Hawton K, Wasserman D, van Heeringen K, Arensman E, Sarchiapone M, Carli V, Höschl C, Barzilay R, Balazs J, Purebl G, Kahn JP, Sáiz PA, Lipsicas CB, Bobes J, Cozman D, Hegerl U, Zohar J.
    TITLE: Suicide prevention strategies revisited: 10-year systematic review.
    The Lancet. Psychiatry. 2016; 3(7):646-59. IF 11.5880
  13. AUTHORS: Bonnin C.M., Torrent C., Arango C., Amann B.L., Sole B., Gonzalez-Pinto A., Crespo J.M., Tabares-Seisdedos R., Reinares M., Ayuso-Mateos J.L., Garcia-Portilla M.P., Ibanez A., Salamero M., Vieta E., Martinez-Aran A.
    TITLE: Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional Outcome.
    British Journal of Psychiatry. 2016;208(1):87-93. IF 6.347
  14. AUTHORS: Martinez-Cengotitabengoa M, MacDowell KS, Alberich S, Diaz FJ, Garcia-Bueno B, Rodriguez-Jimenez R, Bioque M, Berrocoso E, Parellada M, Lobo A, Saiz PA, Matute C, Bernardo M, Gonzalez-Pinto A, Leza JC, FLAMM-PEPs, Arango López Celso.
    TITLE: BDNF and NGF Signalling in Early Phases of Psychosis: Relationship With Inflammation and Response to Antipsychotics After 1 Year.
    Schizophrenia bulletin. 2016; 42(1):142-51. IF 7.5750
  15. AUTHORS: Banzer R., Haring C., Buchheim A., Oehler S., Carli V., Wasserman C., Kaess M., Apter A., Balazs J., Bobes J., Brunner R., Corcoran P., Cosman D., Hoven C.W., Kahn J.P., Keeley H.S., Postuvan V., Podlogar T., Sisask M., Varnik A., Sarchiapone M., Wasserman D.
    TITLE: Factors associated with different smoking status in European adolescents: results of the SEYLE study.
    European Child and Adolescent Psychiatry. 2017;:1-11. IF 3.2950
  16. AUTHORS: Jimenez E., Arias B., Mitjans M., Goikolea J.M., Ruiz V., Brat M., Saiz P.A., Garcia-Portilla M.P., Buron P., Bobes J., Oquendo M.A., Vieta E., Benabarre A.
    TITLE: Clinical features, impulsivity, temperament and functioning and their role in suicidality in patients with bipolar disorder.
    Acta Psychiatrica Scandinavica. 2016; 133(4):266-76. IF 6.790
  17. AUTHORS: Garcia-Portilla MP, Garcia-Alvarez L, Sarramea F, Galvan G, Diaz-Mesa E, Bobes-Bascaran T, Al-Halabi S, Elizagarate E, Iglesias C, Saiz Martínez PA, Bobes J.
    TITLE: It is feasible and effective to help patients with severe mental disorders to quit smoking: An ecological pragmatic clinical trial with transdermal nicotine patches and varenicline.
    Schizophrenia Research. 2016; 176(2-3):272-280. IF 3.986
  18. AUTHORS: Barzilay S., Brunstein Klomek A., Apter A., Carli V., Wasserman C., Hadlaczky G., Hoven C.W., Sarchiapone M., Balazs J., Kereszteny A., Brunner R., Kaess M., Bobes J., Saiz P., Cosman D., Haring C., Banzer R., Corcoran P., Kahn J.-P., Postuvan V., Podlogar T., Sisask M., Varnik A., Wasserman D.
    TITLE: Bullying Victimization and Suicide Ideation and Behavior Among Adolescents in Europe: A 10-Country Study.
    Journal of Adolescent Health. 2017;61(2):179-186. IF 3.974
  19. AUTHORS: Sanchez-Moreno J, Bonnin CM, González-Pinto A, Amann BL, Solé B, Balanzá-Martinez V, Arango C, Jiménez E, Tabarés-Seisdedos R, Garcia-Portilla MP, Ibáñez A, Crespo JM, Ayuso-Mateos JL, Martinez-Aran A, Torrent C., Vieta E, CIBERSAM Functional Remediation Group.
    TITLE: Factors associated with poor functional outcome in bipolar disorder: sociodemographic, clinical, and neurocognitive variables.
    Acta Psychiatrica Scandinavica. 2018 May 3. doi: 10.1111/acps.12894 FI 6,790
  20. AUTHORS: Jongsma H.E., Gayer-Anderson C., Lasalvia A., Quattrone D., Mule A., Szoke A., Selten J.-P., Turner C., Arango C., Tarricone I., Berardi D., Tortelli A., Llorca P.-M., De Haan L., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., Del-Ben C.M., Menezes P.R., Murray R.M., Rutten B.P., Jones P.B., Van Os J., Morgan C., Kirkbride J.B., Reininghaus U., Di Forti M., Hubbard K., Beards S., Stilo S.A., Tripoli G., Parellada M., Cuadrado P., Solano J.J.R., Carracedo A., Bernardo E.G., Roldan L., Lopez G., Cabrera B., Lorente-Rovira E., Garcia-Portilla P., Costas J., Jimenez-Lopez E., Matteis M., Rapado M., Gonzalez E., Martinez C., Sanchez E., Olmeda M.S., Franke N., Velthorst E., Termorshuizen F., Van Dam D., Van Der Ven E., Messchaart E., Leboyer M., Schurhoff F., Jamain S., Frijda F., Baudin G., Ferchiou A., Pignon B., Richard J.-R., Charpeaud T., Tronche A.-M., La Barbera D., La Cascia C., Marrazzo G., Sideli L., Sartorio C., Ferraro L., Seminerio F., Loureiro C.M., Shuhama R., Ruggeri M., Tosato S., Bonetto C., Cristofalo D.
    TITLE: Treated incidence of psychotic disorders in the multinational EU-GEI study.
    JAMA Psychiatry. 2018;75(1):36-46. IF 15.3070
Title Funding Body Reference No Principal Investigator Co-Investigators Duration Funding
Detection of suicidal behaviour risk through a combination of genomic and clinical approaches Instituto de Salud Carlos III, Health Research Fund (FIS) PI17/01433 Pilar Alejandra Sáiz 2018 – 2020 €123,420.00
Construction of a clinical staging model for schizophrenia Instituto de Salud Carlos III (FIS) PI16/01761 Julio Bobes Leticia González Blanco, Isabel Menéndez Miranda, Celso Iglesias García, Eduardo Fonseca Pedrero 2017 – 2019 €67,155.00
Training European Network: Metabolic Dysfunctions associated with the Pharmacological Treatment of Schizophrenia (TREATMENT) European Commission – H2020-MSCA-ITN-2016 721236 Angela Valverde (CSIC) CIBERSAM – Associated Centre – G05: Julio Bobes, María Paz García-Portilla González 2017 – 2019
Inflammatory alterations in mental diseases: the role of Nrf2 and inflammasome pathways CIBERSAM CIBERSAM Intramural Translational Project (2015 funding round) Javier Rubén Caso (G19) Pilar Lopez García (G-03), Julio Bobes García, Pilar Alejandra Saiz Martinez and Celso Iglesias García (G-05), Virginia Soria Tomas and Mikel Urretavizcaya Sarachaga (G-17), Tomás Palomo Álvarez and Noelia Guerra Martin-Polanco (G-19), Francisco Javier De Diego Adeliño (G-21) 2015 – 2016 €30,000
Maternal prenatal stress and HPA axis sensitisation mediated by 11β-HSD2 gene epigenetic signatures and its interplay with childhood psychosocial stress in explaining psychopathology risk in adolescence CIBERSAM CIBERSAM Intramural Translational Project (2015 funding round) Lourdes Fañanás Saura (G08) María Paz García-Portilla (PI), Isabel Menéndez, Lorena de la Fuente, Plácido Llaneza, Ana Escudero 2015 – 2016 €25,000
Validation of Apathy Evaluation Scales (AES) in patients with schizophrenia CIBERSAM BICIBERSAM (May 2015 funding round) María Paz García-Portilla González 2015 – 2016 €8,000
The contribution of common polygenic variation to the prediction of alcohol dependency risk PNSD (Spanish National Drugs Plan) PI14/02037. Multicentre project Javier Costas Costas Gerardo Flórez Menéndez, Elisardo Becoña Iglesias, Pilar Alejandra Sáiz Martínez, Julio Bobes García, María Paz García-Portilla González, Mario Páramo Fernández, Eduardo Paz Silva, José Javier Suárez Rama 2015 – 2017 €83,208
Validation of a clinical staging model for bipolar disorder Instituto de Salud Carlos III (FIS) PI14/02037. Multicentre project with one beneficiary centre María Paz García-Portilla González Pilar Sierra San Miguel, Belén Arranz Martí, Gemma Safont Lacal, Celso Iglesias García 2015 – 2017 €70,020
Neuropsychological functioning and the inflammatory profile in suicidal behaviour Instituto de Salud Carlos III (FIS) PI14/02029. Multicentre project with one beneficiary centre Pilar Alejandra Sáiz Martínez María Teresa Bascarán Fernández, Hilario Blasco Fontecilla, Myriam Hernández Hernández, Mónica Martínez Cengotitabengoa, Luis Jiménez Treviño 2015 – 2017 €100,000
Differential biomarkers of the negative dimension of schizophrenia Instituto de Salud Carlos III (FIS) PI13/02263. Multicentre project: Three centres in Oviedo, one centre in Langreo, Asturias Julio Bobes José María Pelayo Terán, Celso Iglesias García, Leticia García Alvarez 2014 – 2016 €120,697.50
Depression, anxiety and somatic symptoms in primary healthcare centres across the world: CIE-11-AP field study World Health Organization (WHO) CIE-11-AP field study, RPC 565 version 2, 8/4/2013, multicentre project Julio Bobes Celso Iglesias García, Diego Palao Vidal, Francisco Doce Feliz, Francisco José Vaz Leal, José Carlos González Piqueras, Lola Franco Fernández, Pilar López García, Xabier Lertxundi Aginaga 2013 – 2014 Unfunded
Identification of clinical, neurocognitive and genetic prediction variables in the emergence and recurrence of suicidal behaviour in bipolar disorder Instituto de Salud Carlos III (FIS) PI12/00018 Antonio Benabarre Patricia Burón 2013 – 2015 €27,030
Construction of a clinical staging model for bipolar disorder Instituto de Salud Carlos III (FIS) PI11/02493 María Paz García Portilla Gonzalo Galván, Olga Simón 2012 – 2014 €68,000
Clinical and neurobiological determinants of second-episode schizophrenia: a longitudinal study of first psychotic episodes Instituto de Salud Carlos III (FIS) PI11/02704 Miguel Bernardo / Manuel Bousoño Juan María Fernández, Blanca Morales, Gonzalo Galván 2012 – 2015 €68,200
A comparative study of the evolution of cognitive performance in relation to nicotine in patients with schizophrenia Instituto de Salud Carlos III (FIS) PI11/01891 Susana Al-Halabí Manuel Arrojo Romero, Eva Díaz Mesa, Gonzalo Galván, Luis Jiménez Treviño, María Pouso Ríos, Ramón Ramos Ríos 2012 – 2014 €58,118.18
Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) European Commission – 7th Framework Programme (FP7). Large-scale integrating project . Coordinated by: Rene Kahn – Utrecht University. The Netherlands 242114 Celso Arango Miguel Bernardo Arroyo, Julio Bobes García, Julio Sanjuán Arias 2009 – 2014 €11,937,723
Working in Europe to Stop Truancy Among Youth – WE-STAY European Commission – 7th Framework Programme (FP7). Coordinated by: Danuta Wasserman UE-10-WE-STAY-241542 Julio Bobes Pilar Alejandra Sáiz Martínez, Manuel Victor Bousoño Garcia, María Paz García-Portilla González, Juan María Fernandez Domínguez, Luis Jiménez Treviño, Pedro Alberto Marina González, Julia Rodríguez Revuelta, Susana Al-Halabi Diaz, María Teresa Bascarán Fernández 01-05-2010 to 30-04-2013
Physical comorbidity in severe mental disorders: the design, application and evaluation of a programme for improving the general health of the patient Instituto de Salud Carlos III (FIS) PI12/00882 Paula Zurrón Madera José Eloy García García; Raquel Junquera Fernández; María Luisa Prieto Cedrón; Juan Carlos Illescas Escobar 2013 – 2015 €47,795
EUropean network of national schizophrenia networks studying Gene-Environment Interactions – EU-GEI European Commission – 7th Framework Programme (FP7). Coordinated by: Jim van Os – Maastricht University Medical Center, The Netherlands 241909 Celso Arango López Miguel Bernardo Arroyo, Julio Bobes García, Angel Carracedo Alvarez, Julio Sanjuán Arias 2010 – 2015

 

PhD Student Supervisors Title Date Classification
Patricia Rodríguez Suárez María Paz García-Portilla GonzálezJulio Bobes García Physical health in patients with depressive disorders: a naturalistic study October 2014 Summa cum laude
Pedro Trabajo Vega Víctor Alvarez AntuñaManuel Bousoño García Pedro Rodriguez Ponga (1880-1916): the life and work of a psychiatrist from Langreo in Restoration Spain June 2015 Summa cum laude
Isabel Menéndez Miranda María Paz García-Portilla GonzálezJulio Bobes García Functional skills, evaluated using the UPSA scale, in patients with severe mental disorders (schizophrenia and bipolar disorder) June 2015 Summa cum laude
Patricia Burón Fernández Pilar A Sáiz MartínezJulio Bobes García Monitoring suicidal behaviours in Health District IV of Asturias July 2015 Summa cum laude

European Honours

Elisa Seijo Zazo Fernando Seijo FernándezManuel Bousoño García

María Paz García-Portilla González

Deep brain stimulation in patients with Parkinson’s Disease: variation in psychiatric parameters and quality of life September 2015 Summa cum laude

European Honours

Apolonia Sánchez Jiménez Joaquín Fernández García (†)María Paz García-Portilla González Iron deficiency: the impact upon mental health November 2015 Summa cum laude
Eva María Díaz Mesa María Paz García-Portilla GonzálezJulio Bobes García Adaptation to Spanish and validation of the sixth version of the Addiction Severity Index (ASI-6) February 2016 Summa cum laude
Leticia García Álvarez Julio Bobes GarcíaMaría Paz García-Portilla González Differential biomarkers for schizophrenia June 2016 Summa cum laude

European Honours

María Almudena Pousada González Julio Bobes GarcíaSusana Al-Halabí Díaz Physical comorbidity in patients with severe mental disorders: interdisciplinary follow-up and monitoring by the mental health team and primary healthcare June 2017 Summa cum laude
Leticia González Blanco Julio Bobes GarcíaMaría Paz García-Portilla González Oxidative stress and inflammatory balance in the early stages of schizophrenia May 2018 Summa cum laude

European Honours

  1. Title: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
    Phase: II
    Funding Body: ACADIA Pharmaceuticals Inc.
    Reference Number: NCT02970305
    Protocol code: ACP-103-038
    Duration: January 2017 – June 2019
  2. Title: An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression. Safety and Sustenance of Esketamine Treatment Response with Repeated Doses at Intervals Determined by Symptom Severity (SUSTAIN-3)
    Phase: III
    Funding Body: Janssen-Cilag
    Reference Number: EUDRACT 2015-003578-34
    Protocol code: 54135419TRD3008
    Duration: 2017 – 2022
  3. Title: Interventional, Open-label, Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia.
    Phase: III
    Funding Body: H. Lundbeck A/S
    Reference Number: EUDRACT 2015-003284-11
    Protocol code: 16159B
    Duration: 2017 – 2019
  4. Title: A 52-Week, Open-Label, Prospective, Multicentre, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilised on the Paliperidone Palmitate 1-Month Formulation
    Phase: III
    Funding Body: Janssen-Cilag
    Reference Number: NCT02713282
    Protocol code: R092670SCH3015
    PI – Julio Bobes
    Sub-investigators: María Paz García-Portilla González, Pilar A Saiz Martínez
    Duration: 2016 – 2017
  5. Title: Predictors of Real-world Functioning of Schizophrenia Patients in Maintenance Treatment with Monotherapy Antipsychotics . FunREAL
    Funding Body: CIBERSAM – Janssen Internacional
    Duration: 2015 – 2016
  6. Title: Efficacy and Safety of Inhaled Loxapine Compared with IM Antipsychotic in Acutely Agitated Patients with Schizophrenia or Bipolar Disorder
    Phase: IIIb
    Funding Body: Ferrer Internacional, S.A.
    Reference Number: EUDRA CT 2014-000456-29
    Protocol code: FCD-ADA-1401
    Duration: 2015 – 2016
  7. Title: European Long-acting Antipsychotics in Schizophrenia Trial (EULAST) – Clinical Trial –
    Phase: IV
    Funding Body: UMC Utrecht – Foundation European Group for Research In Schizophrenia (EGRIS)
    Reference Number: NCT02146547
    Duration: 2015 – 2017
  8. Title: Randomised, Controlled, Parallel Clinical Trial on the Efficacy of Pharmacogenetic Information Obtained With NEUROFARMAGEN in the Treatment of Patients With Mental Disorders.
Funding Body: AB-BIOTICS S.A.
    Reference Number: EUDRA CT 2013-002228-18
    Protocol code: AB-GEN2013
    Duration: 2014
  9. Title: A Phase 4, Non-Treatment Follow-Up For Cardiac Assessments Following Use Of Different Treatments For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders.
    Reference Number: NCT01574703
    Protocol code: A3051148
    Duration: 2014
  10. Title: A Phase IV Randomised, Double-blind, Active and Placebo-controlled, Multicentre Study Evaluating the Neuropsychiatric Safety and Efficacy of 12 weeks Varenicline Tartrate 1mg Bid for Smoking Cessation in Subjects with and without a History of Psychiatric Disorders.
    Reference Number: NCT01456936
    Protocol code: A3051123
    Duration: 2014
  11. Title: A Phase 4, E uropean Non-Interventional Study (NIS) in Patients with Schizophrenia Treated with Antipsychotic Long-Acting Injections (LAIs).
    Protocol code: 14782A
    Duration: 2013
  12. Title: A Prospective, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients With Bipolar I Disorder.
    Reference Number: NCT01674010
    Protocol code: ELND005-BPD201
    Duration: 2013
  13. Title: A Phase 3, Open-label, Multicentre, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant.
    Reference Number: NCT01436175
    Protocol code: SPD489-329
    Duration: 2013
  14. Title: The SPD489-322 Phase 3, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy, and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.
    Reference Number: NCT01436149
    Protocol code: SPD489-322
    Duration: 2013
  15. Title: A Phase III, Multicentre, Randomised, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients with Persistent, Predominant Negative Symptoms of Schizophrenia Treated with Antipsychotics Followed by a 28 Week Double-blind Treatment Period.
    Protocol code: WN25309
    EudraCT: 2010-020467-21
    Duration: 2012 – 2014
  16. Title: Phase III, Multicentre, Randomised, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients with Sub-optimally Controlled Symptoms of Schizophrenia Treated with Antipsychotics Followed by a 40-week Double-blind, Parallel Group, Placebo-controlled Treatment Period.
    Protocol code: WN25306
    Eudra CT: 2010-020616-11
    Duration: 2012 – 2014